236 related articles for article (PubMed ID: 37984256)
1. Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors.
Wang TW; Chao HS; Chiu HY; Lu CF; Liao CY; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Transl Oncol; 2024 Jan; 39():101826. PubMed ID: 37984256
[TBL] [Abstract][Full Text] [Related]
2. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
4. Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With
Tang X; Li Y; Yan WF; Qian WL; Pang T; Gong YL; Yang ZG
Front Oncol; 2021; 11():719919. PubMed ID: 34660285
[TBL] [Abstract][Full Text] [Related]
5. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
6. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC.
Fan Y; Wang X; Dong Y; Cui E; Wang H; Sun X; Su J; Luo Y; Yu T; Jiang X
Eur Radiol; 2023 Nov; 33(11):7902-7912. PubMed ID: 37142868
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
Qi H; Hou Y; Zheng Z; Zheng M; Qiao Q; Wang Z; Sun X; Xing L
BMC Cancer; 2024 Mar; 24(1):362. PubMed ID: 38515096
[TBL] [Abstract][Full Text] [Related]
8. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis.
Qi H; Hou Y; Zheng Z; Zheng M; Sun X; Xing L
Clin Radiol; 2024 Jul; 79(7):515-525. PubMed ID: 38637187
[TBL] [Abstract][Full Text] [Related]
9. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Qu J; Zhang T; Zhang X; Zhang W; Li Y; Gong Q; Yao L; Lui S
Clin Radiol; 2024 Apr; 79(4):e582-e591. PubMed ID: 38310058
[TBL] [Abstract][Full Text] [Related]
10. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
11. Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature.
Zhang X; Lu B; Yang X; Lan D; Lin S; Zhou Z; Li K; Deng D; Peng P; Zeng Z; Long L
Eur Radiol; 2023 Feb; 33(2):825-835. PubMed ID: 36166088
[TBL] [Abstract][Full Text] [Related]
12. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].
Chen L; Fu M; Zhou J; Yao Y; Zhou J
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
[TBL] [Abstract][Full Text] [Related]
15. Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis.
Fan Y; Wang X; Yang C; Chen H; Wang H; Wang X; Hou S; Wang L; Luo Y; Sha X; Yang H; Yu T; Jiang X
J Magn Reson Imaging; 2023 Dec; 58(6):1838-1847. PubMed ID: 37144750
[TBL] [Abstract][Full Text] [Related]
16. Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?
Yang X; Fang C; Li C; Gong M; Yi X; Lin H; Li K; Yu X
Front Oncol; 2022; 12():904983. PubMed ID: 35875167
[TBL] [Abstract][Full Text] [Related]
17. Combined radiomics of primary tumour and bone metastasis improve the prediction of EGFR mutation status and response to EGFR-TKI therapy for NSCLC.
Cheng Y; Wang H; Yuan W; Wang H; Zhu Y; Chen H; Jiang W
Phys Med; 2023 Dec; 116():103177. PubMed ID: 38000098
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
[TBL] [Abstract][Full Text] [Related]
19. A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study.
Deng K; Wang L; Liu Y; Li X; Hou Q; Cao M; Ng NN; Wang H; Chen H; Yeom KW; Zhao M; Wu N; Gao P; Shi J; Liu Z; Li W; Tian J; Song J
EClinicalMedicine; 2022 Sep; 51():101541. PubMed ID: 35813093
[TBL] [Abstract][Full Text] [Related]
20. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced
He ZY; Li MF; Lin JH; Lin D; Lin RJ
Cancer Manag Res; 2019; 11():2129-2138. PubMed ID: 30936745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]